{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PCD&page=19", "query": { "intervention": "PCD", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 456, "total_pages": 46, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PCD&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PCD&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T23:33:52.522Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03848182", "title": "Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "TT vaccine booster", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Albert Einstein College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 10, "start_date": "2017-07-21", "completion_date": "2019-11-11", "has_results": true, "last_update_posted_date": "2024-04-18", "last_synced_at": "2026-10-23T23:33:52.522Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03848182" }, { "nct_id": "NCT06508463", "title": "Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Peripheral T Cell Lymphoma", "Relapsed Peripheral T-Cell Lymphoma", "Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Anaplastic Large Cell Lymphoma", "Mycosis Fungoides", "Relapsed Anaplastic Large Cell Lymphoma", "Relapsed Mycosis Fungoides" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter", "type": "BIOLOGICAL" }, { "name": "Single Photon Emission Computed Tomography", "type": "PROCEDURE" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2024-01-05", "completion_date": "2032-04-01", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-23T23:33:52.522Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06508463" }, { "nct_id": "NCT02716038", "title": "Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "MPDL3280A", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2016-06-07", "completion_date": "2022-10-01", "has_results": true, "last_update_posted_date": "2023-12-12", "last_synced_at": "2026-10-23T23:33:52.522Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02716038" }, { "nct_id": "NCT01886807", "title": "The Use of Apneic Oxygenation During Prolonged Intubation in Pediatric Patients: a Randomized Clinical Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Intubation of Pediatric Dental Surgery Patients" ], "interventions": [ { "name": "TrueView PCD Video Laryngoscope", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 482, "start_date": "2013-06", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2019-04-11", "last_synced_at": "2026-10-23T23:33:52.522Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01886807" }, { "nct_id": "NCT03639844", "title": "BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Hurler Syndrome", "Inherited Metabolic Disorder", "Lysosomal Storage Disorder", "Metachromatic Leukodystrophy", "Inborn Errors of Metabolism" ], "interventions": [ { "name": "rivogenlecleucel", "type": "BIOLOGICAL" }, { "name": "rimiducid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bellicum Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "3 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Months to 21 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2020-10-05", "last_synced_at": "2026-10-23T23:33:52.522Z", "location_count": 2, "location_summary": "Los Angeles, California • Palo Alto, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03639844" }, { "nct_id": "NCT03976375", "title": "Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 422, "start_date": "2019-06-26", "completion_date": "2024-08-22", "has_results": true, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-10-23T23:33:52.522Z", "location_count": 28, "location_summary": "Bakersfield, California • Fleming Island, Florida • Orange City, Florida + 24 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Fleming Island", "state": "Florida" }, { "city": "Orange City", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03976375" }, { "nct_id": "NCT03388632", "title": "Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Solid Tumors", "Treatment-Refractory Cancers" ], "interventions": [ { "name": "rhIL-15", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Tumor biopsies", "type": "PROCEDURE" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "ECHO", "type": "DIAGNOSTIC_TEST" }, { "name": "CT Scan", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "PROCEDURE", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 31, "start_date": "2018-02-05", "completion_date": "2025-05-08", "has_results": true, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-10-23T23:33:52.522Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03388632" }, { "nct_id": "NCT03563248", "title": "Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "FOLFIRINOX", "type": "DRUG" }, { "name": "Losartan", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "SBRT", "type": "RADIATION" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2018-08-10", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2025-10-01", "last_synced_at": "2026-10-23T23:33:52.522Z", "location_count": 10, "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03563248" }, { "nct_id": "NCT00433992", "title": "Metabolic Effects of Non-Thymidine Analogue Anti-HIV Medications", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Infections" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2006-04", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2017-09-05", "last_synced_at": "2026-10-23T23:33:52.522Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00433992" }, { "nct_id": "NCT03727841", "title": "Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaplastic Ependymoma", "Ependymoma", "Ependymomas" ], "interventions": [ { "name": "Marizomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 4, "start_date": "2020-01-22", "completion_date": "2021-04-30", "has_results": true, "last_update_posted_date": "2022-07-27", "last_synced_at": "2026-10-23T23:33:52.522Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03727841" } ] }